Letterman Army Hospital

A.D.A.M., Developers of Innovative 3D Bone Implant Biotech, Announces Chief Medical Officer

Retrieved on: 
Tuesday, January 25, 2022

was launched to disrupt the surgical implant industry currently dominated by costly and more invasive titanium implants.

Key Points: 
  • was launched to disrupt the surgical implant industry currently dominated by costly and more invasive titanium implants.
  • The biotech startup specializes in 3D printed bone implants made using biopolymers and bioceramics.
  • Engaging Dr. Savory as CMO is a key milestone for the company, as he is a well-respected expert in orthopaedic surgery.
  • He graduated from the United States Military Academy in 1967 and served in the Vietnam War as a Platoon Leader.

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

Retrieved on: 
Wednesday, January 19, 2022

SAN DIEGO and SUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biotech company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the appointment of David Gandara, M.D., to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Gandara, Professor Emeritus and Senior Advisor of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), brings deep knowledge and understanding to the immuno-oncology field, and he is recognized for his translational research and clinical work in cancer drug and biomarker development.

Key Points: 
  • Dr. Gandara commented, "I am delighted to join Adagenes SAB at such an exciting time in the company's evolution.
  • Together we look forward to maximizing the potential of our platform to transform immunotherapy for cancer patients across the world.
  • For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/
    Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotech company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
  • Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.